Viaderma Inc (OTCMKTS:VDRM) Continues to Trend Higher on New Developments

Viaderma Inc (OTCMKTS:VDRM) continues to surge on new developments of entering a $3+ billion market, giving investors reason to be excited. The company just announced that it will be initiating an upcoming field trial of comparison for Onychomycosis. The stock has surged over 50% in trading today and the stock has tripled since the beginning of March. VDRM has seen a significant expansion in volume which is a bullish development.

VDRM is attempting to break into the Onychomycosis market with its TetraStem liquid based antibiotic. The market size of Onychomycosis treatment is estimated to be at approximately $3.5 billion in the USA markets alone. Onychomycosis is a fungal infection of the toenails or fingernails that may involve any part of the nail itself. This infection can cause pain, distress, and deformity that could produce serious physical and occupational restrictions, as well as affect quality of life. Recently registered as a medication by the FDA, TetraStem, that is designed to treat cuts, scrapes, and burns.

Viaderma Inc (OTCMKTS:VDRM) introduced an upcoming trial that is expected to take place in the Springtime. The study will feature their leading product, TetraStem. In the trials patients will receive both treatments at 90-day, six months, nine months, and one year lapses of time. Previously used as an off-label treatment for Onychomycosis with proven results, ViaDerma believes that TetraStem will serve as a possible more effective and more affordable option than other leading brands.

The company’s flagship product TetraStem has been seen in private off-label practice to hold an 86% success rate after only 12 weeks of use. Current competition has only seen an 18% success rate, requiring 48 weeks of patient use. Not only are these differences staggering, but to add to that, a bottle of TetraStem retails for only $39.99, whereas the same size has been sold for more than $500 through other brands.

VDRM was founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.

We have a Monster Pick Coming. Subscribe Right Now!
[newsletter_form]

VDRM is currently trading at a $0.5 million market valuation. The company is gaining momentum as it continues to develop its flagship product. It is attempting to disrupt a multi-billion dollar market and is poised for more gains if the study shows statistically significant results. This exciting story is just beginning to heat up. Stay tuned for more info.

We will be updating on VDRM when more details emerge so make sure you are subscribed to Microcapspot so you know what’s going on with VDRM.

Disclosure: we hold no position in VDRM either long or short at the publication of this article and we have not been compensated for this article.